• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

能够互补E1、E4和IX蛋白缺陷型5型腺病毒突变体的细胞系的开发。

Development of cell lines capable of complementing E1, E4, and protein IX defective adenovirus type 5 mutants.

作者信息

Krougliak V, Graham F L

机构信息

Department of Biology, McMaster University, Hamilton, Ontario, Canada.

出版信息

Hum Gene Ther. 1995 Dec;6(12):1575-86. doi: 10.1089/hum.1995.6.12-1575.

DOI:10.1089/hum.1995.6.12-1575
PMID:8664382
Abstract

The cloning capacity of currently available E1- and E3-deleted adenovirus (Ad) vectors does not exceed 8 kb. To increase capacity and improve vector safety further, we have explored the possibility that Early Region 4 (E4) and the gene encoding protein IX (pIX) might also be deleted. To generate cell lines expressing sufficient levels of E4 and pIX proteins in trans in addition to E1-encoded proteins to complement mutations in these genes, we transformed 293 cells with constructs containing the E4 transcription unit and pIX coding sequences under the control of inducible mouse mammary tumor virus (MMTV) and metallothionein promoters, respectively. We obtained two lines, VK2-20 and VK10-9, that express both E4 and pIX proteins as well as E1. The lines could be efficiently transfected with DNA, and allowed the rescue and propagation of an adenovirus; recombinant, Ad5dlE3,4, containing a 2.7-kb E3 deletion and a 2.8-kb E4 deletion in addition to an insertion of plasmid DNA sequences in E1A. Because the E4 sequences within VK2-20 and VK10-9 cells do not overlap with the DNA sequence of Ad5dlE3,E4, the probability of regeneration of the wild-type E4 during virus propagation should be very low. Using the cell lines described in this study, it should be possible to generate Ad vectors lacking E1, pIX, E3, and E4. This would not only increase capacity over that of currently available vectors (to approximately 11 kb) but would also result in more severely attenuated vectors than those with deletions only of E1 or of E1 and E3 and, hence, safer for use in gene therapy protocols.

摘要

目前可用的E1和E3缺失型腺病毒(Ad)载体的克隆能力不超过8 kb。为了增加容量并进一步提高载体安全性,我们探讨了是否也可以删除早期区域4(E4)和编码IX蛋白(pIX)的基因。为了构建除了表达E1编码蛋白外还能反式表达足够水平的E4和pIX蛋白以互补这些基因中突变的细胞系,我们分别用含有在可诱导的小鼠乳腺肿瘤病毒(MMTV)和金属硫蛋白启动子控制下的E4转录单元和pIX编码序列的构建体转化293细胞。我们获得了两个细胞系VK2-20和VK10-9,它们既能表达E4和pIX蛋白,也能表达E1。这些细胞系能够高效地用DNA转染,并能拯救和繁殖腺病毒;重组腺病毒Ad5dlE3,4,除了在E1A中插入质粒DNA序列外,还含有2.7 kb的E3缺失和2.8 kb的E4缺失。由于VK2-20和VK10-9细胞中的E4序列与Ad5dlE3,E4的DNA序列不重叠,在病毒繁殖过程中野生型E4再生的可能性应该非常低。使用本研究中描述的细胞系,应该有可能产生缺失E1、pIX、E3和E4的Ad载体。这不仅会比目前可用的载体增加容量(达到约11 kb),而且会产生比仅缺失E1或E1和E3的载体更严重减毒的载体,因此在基因治疗方案中使用更安全。

相似文献

1
Development of cell lines capable of complementing E1, E4, and protein IX defective adenovirus type 5 mutants.能够互补E1、E4和IX蛋白缺陷型5型腺病毒突变体的细胞系的开发。
Hum Gene Ther. 1995 Dec;6(12):1575-86. doi: 10.1089/hum.1995.6.12-1575.
2
Efficient dual transcomplementation of adenovirus E1 and E4 regions from a 293-derived cell line expressing a minimal E4 functional unit.来自表达最小E4功能单元的293衍生细胞系的腺病毒E1和E4区域的高效双转互补。
J Virol. 1996 Jan;70(1):559-65. doi: 10.1128/JVI.70.1.559-565.1996.
3
Novel complementation cell lines derived from human lung carcinoma A549 cells support the growth of E1-deleted adenovirus vectors.源自人肺癌A549细胞的新型互补细胞系支持E1缺失腺病毒载体的生长。
Gene Ther. 1996 Jan;3(1):75-84.
4
A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4.一种用于腺病毒早期区域E1和E4完全功能互补的基因转移载体-细胞系系统。
J Virol. 1996 Sep;70(9):6497-501. doi: 10.1128/JVI.70.9.6497-6501.1996.
5
Generation of an adenovirus vector lacking E1, e2a, E3, and all of E4 except open reading frame 3.生成一种腺病毒载体,其缺乏E1、E2a、E3以及除开放阅读框3之外的所有E4。
J Virol. 1999 Jul;73(7):6048-55. doi: 10.1128/JVI.73.7.6048-6055.1999.
6
Generation and characterization of E1/E2a/E3/E4-deficient adenoviral vectors encoding human factor VIII.编码人凝血因子VIII的E1/E2a/E3/E4缺陷型腺病毒载体的构建与鉴定
Mol Ther. 2001 Mar;3(3):329-36. doi: 10.1006/mthe.2001.0264.
7
Reduced toxicity, attenuated immunogenicity and efficient mediation of human p53 gene expression in vivo by an adenovirus vector with deleted E1-E3 and inactivated E4 by GAL4-TATA promoter replacement.通过GAL4-TATA启动子替换缺失E1-E3并使E4失活的腺病毒载体,降低体内毒性、减弱免疫原性并有效介导人p53基因表达。
Gene Ther. 1999 Mar;6(3):393-402. doi: 10.1038/sj.gt.3300825.
8
A packaging cell line for propagation of recombinant adenovirus vectors containing two lethal gene-region deletions.一种用于繁殖含有两个致死基因区域缺失的重组腺病毒载体的包装细胞系。
Gene Ther. 1995 Dec;2(10):775-83.
9
Protease-deleted adenovirus vectors and complementing cell lines: potential applications of single-round replication mutants for vaccination and gene therapy.缺失蛋白酶的腺病毒载体与互补细胞系:单轮复制突变体在疫苗接种和基因治疗中的潜在应用
Hum Gene Ther. 2000 Jun 10;11(9):1341-53. doi: 10.1089/10430340050032438.
10
In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted.E1、E1/E2A或E1/E4缺失的重组腺病毒载体的体外和体内生物学特性
J Virol. 1998 Mar;72(3):2022-32. doi: 10.1128/JVI.72.3.2022-2032.1998.

引用本文的文献

1
Viral and Non-Viral Systems to Deliver Gene Therapeutics to Clinical Targets.病毒和非病毒系统将基因治疗递送至临床靶标。
Int J Mol Sci. 2024 Jul 4;25(13):7333. doi: 10.3390/ijms25137333.
2
Advances of Recombinant Adenoviral Vectors in Preclinical and Clinical Applications.腺相关病毒载体在临床前和临床应用中的进展。
Viruses. 2024 Feb 28;16(3):377. doi: 10.3390/v16030377.
3
Adenoviral Gene Therapy Vectors in Clinical Use-Basic Aspects with a Special Reference to Replication-Competent Adenovirus Formation and Its Impact on Clinical Safety.
临床应用的腺病毒基因治疗载体 - 以复制型腺病毒形成及其对临床安全性的影响为例的基本方面。
Int J Mol Sci. 2023 Nov 20;24(22):16519. doi: 10.3390/ijms242216519.
4
Enforced DNA repair enzymes rescue neurons from apoptosis induced by target deprivation and axotomy in mouse models of neurodegeneration.在神经退行性疾病小鼠模型中,强制表达DNA修复酶可挽救因靶标剥夺和轴突切断诱导凋亡的神经元。
Mech Ageing Dev. 2017 Jan;161(Pt A):149-162. doi: 10.1016/j.mad.2016.06.011. Epub 2016 Jun 27.
5
Suppression of leaky expression of adenovirus genes by insertion of microRNA-targeted sequences in the replication-incompetent adenovirus vector genome.通过在复制缺陷型腺病毒载体基因组中插入 microRNA 靶向序列抑制腺病毒基因的漏表达。
Mol Ther Methods Clin Dev. 2014 Sep 3;1:14035. doi: 10.1038/mtm.2014.35. eCollection 2014.
6
RNA interference with special reference to combating viruses of crustacea.RNA干扰及其在对抗甲壳类病毒方面的特殊应用。
Indian J Virol. 2012 Sep;23(2):226-43. doi: 10.1007/s13337-012-0084-1. Epub 2012 Aug 14.
7
GUCY2C-targeted cancer immunotherapy: past, present and future.靶向 GUCY2C 的癌症免疫疗法:过去、现在和未来。
Immunol Res. 2011 Dec;51(2-3):161-9. doi: 10.1007/s12026-011-8253-7.
8
Adenoviral producer cells.腺病毒生产细胞。
Viruses. 2010 Aug;2(8):1681-1703. doi: 10.3390/v2081681. Epub 2010 Aug 16.
9
Integrin alphavbeta5 is a primary receptor for adenovirus in CAR-negative cells.整合素 alphavbeta5 是 CAR 阴性细胞中腺病毒的主要受体。
Virol J. 2010 Jul 8;7:148. doi: 10.1186/1743-422X-7-148.
10
Gene transfer into neural cells in vitro using adenoviral vectors.使用腺病毒载体在体外将基因导入神经细胞。
Curr Protoc Neurosci. 2008 Oct;Chapter 4:Unit 4.23. doi: 10.1002/0471142301.ns0423s45.